Falls: a marker of preclinical Alzheimer disease: a cohort study protocol
Guardado en:
Autores principales: | John C Morris, Susan L Stark, Rebecca M Bollinger, Audrey Keleman, Regina Thompson, Elizabeth Westerhaus, Anne M Fagan, Tammie LS Benzinger, Suzanne E Schindler, Chengjie Xiong, David Balota, Beau M Ances |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/48f5aaf10d1c432faa119e41b4653dbe |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer’s disease
por: Stephan Müller, et al.
Publicado: (2017) -
Where We Fall Down: Tensions in Teaching Social Medicine and Global Health
por: Amy Finnegan, et al.
Publicado: (2017) -
Alterations in erythrocyte fatty acid composition in preclinical Alzheimer’s disease
por: Kathryn Goozee, et al.
Publicado: (2017) -
Retinal ganglion cell dysfunction in preclinical Alzheimer’s disease: an electrophysiologic biomarker signature
por: Samuel Asanad, et al.
Publicado: (2021) -
Disease progression modelling from preclinical Alzheimer’s disease (AD) to AD dementia
por: Soo Hyun Cho, et al.
Publicado: (2021)